Recombinant rota virus expression system and recombinant rota viruses

US2025171502A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025171502-A1
Application numberUS-202418946551-A
CountryUS
Kind codeA1
Filing dateNov 13, 2024
Priority dateJul 13, 2018
Publication dateMay 29, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).

First claim

Opening claim text (preview).

What is claimed is: 1 . A recombinant rotavirus comprising: a gene segment including a nucleotide sequence encoding at least one nucleotide sequence selected from the group consisting of: rotavirus nonstructural protein 1 (NSP1), rotavirus nonstructural protein 3 (NSP3), rotavirus nonstructural protein 5 (NSP5); and a nucleotide sequence encoding a non rotavirus polypeptide, wherein the (i) NSP1, NSP3, or NSP5 and (ii) the non-rotavirus polypeptide are encoded by a single open reading frame, separated by a self-cleavage protease domain. 2 . The recombinant rotavirus of claim 1 , wherein the self-cleavage protease domain is a 2A cleavage element. 3 . The recombinant rotavirus of claim 1 , wherein the self-cleavage protease domain is a tesco porcine virus 2A (P2A) element. 4 . The recombinant rotavirus of claim 3 , wherein the P2A element has a sequence having at least 80% sequence identity to SEQ ID NO: 1 (S KF QID KILIS GDIELNPGP). 5 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is derived from a virus that causes gastroenteritis. 6 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is derived from a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, enterovirus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus. 7 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a second virus that is not rotavirus. 8 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, enterovirus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picomavirus, and coronavirus. 9 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is selected from the group consisting of norovirus VP1 protein, noro virus P domain, and norovirus P2 domain. 10 . The recombinant rotavirus of claim 1 , wherein the recombinant rotavirus is based upon strain GIP. 11 . The recombinant rotavirus of claim 1 , wherein the recombinant rotavirus is attenuated.

Assignees

Inventors

Classifications

  • Methods of production or purification of viral material · CPC title

  • Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

  • New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

  • Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

  • Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025171502A1 cover?
Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, c…
Who is the assignee on this patent?
Univ Indiana Trustees
What technology area does this patent fall under?
Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu May 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).